



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address : COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
160,795	06/19/80	Frank Villani	2206

EXAMINER	
Schwartz	
ART UNIT	PAPER NUMBER
121	4

DATE MAILED:

**EXAMINER INTERVIEW SUMMARY RECORD**

All participants (applicant, attorney, agent) representing applicant:

(1) Mr. Ginsburg (3) \_\_\_\_\_  
(2) \_\_\_\_\_ (4) \_\_\_\_\_

Date of interview 12/09/80

Type: ☒ Telephonic ☐ Personal (copy is given to applicant).

Exhibit shown or demonstration conducted: ☐ Yes ☒ No.

Agreement ☒ was reached with respect to some or all of the claims in question. ☐ was not reached.

Claims discussed: 1-14

Identification of prior art discussed: None

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: \_\_\_\_\_

Examiner objected to the word "substituted" in Claim 1. Mr. Ginsburg agreed to combine claims 1 & 2 to expedite prosecution without necessarily acquiescing to the Examiner's position that the disputed word encompasses subject matter beyond the scope of the enablement. Applicants' amendments at page 2 will be cancelled; support exists for R as C<sub>1</sub>-C<sub>12</sub> alkyl, but not for such as a preferred embodiment. Subject matter of claim 2 will be inserted into the specification. Title of Example 5 will be corrected to conform to claim 9. Claim 13 will be amended to reflect antihistaminic utility and dependence on specific claims. Above changes to be effected by Examiner's amendment. Examiner questioned nomenclature of species claims. Mr. Ginsburg conferred with applicant who will supply an explanation. Examiner later called Mr. Ginsburg again, indicating that he had satisfied himself of the correctness of the nomenclature.

(A fuller necessary description and any available copy of amendments that the examiner agreed would render the claims allowable, or where no copy of the amendments is available, a summary thereof, is attached.)

The word "novel" to be deleted from abstract and from title.

☒ It is not necessary for applicant to supplement the information on this form or to submit a separate record of the substance of the interview.

Claim 2: aralkyl to read phenylalkyl (support at page 6, line 3)

**APPLICANTS, ATTORNEYS AND AGENTS ARE REMINDED OF THEIR RESPONSIBILITY TO SUPPLEMENT THIS RECORD WITH AN INDICATION OF THE SUBSTANCE OF THE INTERVIEW AS REQUIRED BY 37 CFR 1.133(b) AND SECTION 713.04 OF THE MANUAL OF PATENT EXAMINING PROCEDURE. (See reverse side for text of Section 713.04.)**